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Abstract Diruthenium tetracarbonyl complexes of the
type [Ru2(CO)4(l2-g
2-O2CR)2L2] containing a Ru–Ru
backbone with four equatorial carbonyl ligands, two car-
boxylato bridges, and two axial two-electron ligands in a
sawhorse-like geometry have been synthesized with por-
phyrin-derived substituents in the axial ligands [1: R is CH3,
L is 5-(4-pyridyl)-10,15,20-triphenyl-21,23H-porphyrin], in
the bridging carboxylato ligands [2: RCO2H is 5-(4-
carboxyphenyl)-10,15,20-triphenyl-21,23H-porphyrin, L is
PPh3; 3: RCO2H is 5-(4-carboxyphenyl)-10,15,20-triphe-
nyl-21,23H-porphyrin, L is 1,3,5-triaza-7-phosphatricyclo
[3.3.1.1]decane], or in both positions [4: RCO2H is 5-(4-
carboxyphenyl)-10,15,20-triphenyl-21,23H-porphyrin, L is
5-(4-pyridyl)-10,15,20-triphenyl-21,23H-porphyrin]. Com-
pounds 1–3 were assessed on different types of human
cancer cells and normal cells. Their uptake by cells was
quantified by fluorescence and checked by fluorescence
microscopy. These compounds were taken up by human
HeLa cervix and A2780 and Ovcar ovarian carcinoma cells
but not by normal cells and other cancer cell lines (A549
pulmonary, Me300 melanoma, PC3 and LnCap prostate,
KB head and neck, MDAMB231 and MCF7 breast, or
HT29 colon cancer cells). The compounds demonstrated no
cytotoxicity in the absence of laser irradiation but exhibited
good phototoxicities in HeLa and A2780 cells when
exposed to laser light at 652 nm, displaying an LD50
between 1.5 and 6.5 J/cm2 in these two cell lines and more
than 15 J/cm2 for the others. Thus, these types of porphyric
compound present specificity for cancer cell lines of the
female reproductive system and not for normal cells; thus
being promising new organometallic photosensitizers.
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Introduction
Photodynamic therapy is a modality of treatment already
used in the clinic for cancer treatment [1–4]. It involves a
nontoxic photoactivable dye called a ‘‘photosensitizer’’ in
combination with harmless visible light of a specific
wavelength to excite the photosensitizer. The photosensi-
tizer reaches a high-energy triplet state which reacts with
cellular oxygen to form toxic reactive oxygen species such
as singlet oxygen and oxygen radicals which will oxidize
cellular nuclei, fatty, and amino acids. The photosensitizers
commonly bear a tetrapyrrolic ring such as porphyrins,
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chlorins, or bacteriochlorins and have been shown to con-
centrate in cancer cells [3, 5, 6]. On the other hand,
organometallic drugs, especially platinum derivatives, are
commonly used in cancer therapy [7–9]. However, signif-
icant problems associated with platinum compounds limit
their applicability, including a high general toxicity and
drug resistance by several types of cancer [10, 11]. Some
progress has been made to overcome these limitations with
other organometallics such as ruthenium-based agents [12].
Ruthenium is an attractive alternative to platinum since
ruthenium compounds are known to display less general
toxicity than their platinum counterparts, but are also able
to interact with DNA and proteins [13]. Moreover, ruthe-
nium derivatives are believed to be taken up by cells via
the transferrin receptor system in particular and present
some selectivity for cancer cell lines [12].
Combining both an organometallic group with a por-
phyric photosensitizing moiety could therefore represent a
promising approach. Complexes of porphyrins coordinated
to platinum groups were developed mainly by Lottner
et al. a few years ago and show some promise [14–18].
More recently, we have coordinated arene–ruthenium(II)
moieties to pyridylporphyrins and such complexes showed
good cytotoxicities and phototoxicities toward human
melanoma cancer cells [19, 20]. In this study, we have
chosen the diruthenium tetracarbonyl structure as the
organometallic agent and backbone of the complexes.
These sawhorse-type diruthenium complexes have been
known since 1969, when J. Lewis and co-workers [21]
reported the formation of [Ru2(CO)4(l2-g
2-O2CR)2]n
polymers by refluxing [Ru3(CO)12] in the corresponding
carboxylic acid (HO2CR), and the depolymerization of
these materials in coordinating solvents to give dinuclear
complexes of the type [Ru2(CO)4(l2-g
2-O2CR)2L2], L
being acetonitrile, pyridine, or other two-electron donor
ligands (Structure 1).
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Structure 1
Herein, we describe the synthesis, the spectroscopic
characterization, the electrochemical behavior, and the
biological activity in human normal fibroblastic cells and in
many types of human cancer cells of diruthenium tetra-
carbonyl complexes of the type [Ru2(CO)4(l2-g
2-O2
CR)2L2] containing porphyrin substituents: [Ru2(CO)4
(l2-g
2-O2CCH3)2(C43H29N5)2] (1), [Ru2(CO)4(l2-g
2-O2
CC44H29N4)2(PPh3)2] (2), [Ru2(CO)4(l2-g
2-O2CC44H29N4)2
(pta)2] (pta is 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane)
(3), and [Ru2(CO)4(l2-g
2-O2CC44H29N4)2(C43H29N5)2] (4).
Experimental
Materials and methods
All manipulations were carried out by conventional
Schlenk techniques under a nitrogen atmosphere. Organic
solvents were dried, degassed, and saturated with nitrogen
prior to use. All reagents were purchased from Aldrich,
Fluka, and Porphyrin Systems and used as received.
Dodecacarbonyltriruthenium [22] and 1,3,5-triaza-7-
phosphatricyclo[3.3.1.1]decane (pta) [23] were prepared
according to published methods. NMR spectra were
recorded at 25 C using a Bruker 400 MHz spectrometer.
IR spectra were recorded using a PerkinElmer 1720X
Fourier transform IR spectrometer (4,000–400 cm-1).
UV–vis absorption spectra were recorded with a Uvikon 930
spectrophotometer. Microanalyses were performed by the
Laboratory of Pharmaceutical Chemistry, University of
Geneva (Switzerland). Electrospray mass spectra studies
were realized using an APEX II Fourier transform ion
cyclotron resonance mass spectrometer equipped with
a 9.4-T superconducting magnet (Bruker Daltonics).
Electrochemical measurements were carried out with a
computer-controlled lAUTOLAB III multipurpose
polarograph (Eco Chemie, The Netherlands) at room
temperature using a Metroohm three-electrode cell with a
rotating platinum disc electrode (AUTOLAB RDE; 3-mm
diameter) as the working electrode, a platinum sheet aux-
iliary electrode, and an Ag/AgCl reference electrode (3 M
KCl). The compounds analyzed were dissolved in dichlo-
romethane (Fluka, absolute; declared H2O content 0.005%
or less) to give a solution containing 5 9 10-4 M of the
analyte and 0.1 M Bu4NPF6 (Fluka, purissimum for elec-
trochemistry). In the case of poorly soluble compounds,
saturated solutions were used. The solutions were degassed
and saturated with argon prior to the measurement and then
kept under an argon blanket. The redox potentials are given
relative to an internal ferrocene/ferrocenium reference.
Quantum yields were assessed after excitation at 414 nm as
previously described [20]. Fluorescence quantum yields at
648 nm were determined using a PerkinElmer LS50
spectrofluorometer. The singlet oxygen quantum yield was
determined using the singlet oxygen specific fluorescence
at 1,270 nm monitored by a liquid-nitrogen-cooled ger-
manium detector (model EO-817L, North Coast Scientific)
from the DCPR facility, ENSIC, Nancy, France.
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Synthesis of complexes 1–4
A solution of [Ru3(CO)12] (1 equiv, typically 15–50 mg)
and 3 equiv of the corresponding acid [5 mg of acetic acid
for 1, 100 mg of 5-(4-carboxyphenyl)-10,15,20-triphenyl-
21,23H-porphyrin for 2, 155 mg of 5-(4-carboxyphenyl)-
10,15,20-triphenyl-21,23H-porphyrin for 3, 55 mg of
5-(4-carboxyphenyl)-10,15,20-triphenyl-21,23H-porphyrin
for 4] in dry tetrahydrofuran (THF; 30 mL) were heated at
120 C in a pressure Schlenk tube for 18 h. Then the sol-
vent was evaporated to give a purple or brown residue
which was dissolved in THF and 3 equiv of the appropriate
ligand L [L is 5-(4-pyridyl)-10,15,20-triphenyl-21,23H-
porphyrin for 1 and 4, PPh3 for 2, and L is pta for 3] was
added. The solution was stirred at room temperature for
2 h, the solution was evaporated, and the product was
isolated by precipitation from a THF/hexane mixture. All
products were obtained as air-stable purple crystalline
powders.
Spectroscopic data for 1
Yield: 55 mg (83%). 1H NMR (400 MHz, CDCl3)
d = -2.75 (s, 4H, NH), 2.37 (s, 6H, CH3), 7.76–7.86 (m, 18H,
C6H5), 8.23–8.27 (m, 12H, C6H5), 8.38 (d, 4H,
3J = 6 Hz,
Hpyr), 8.90 (s, 8H, Hporph), 8.99 (s, 8H, Hporph), 9.24 (d, 4H,
3J = 6 Hz, Hpyr).
13C {1H} NMR (100 MHz, CDCl3)
d = 24.27 (CH3), 94.30, 99.92, 101.59, 115.25, 120.97,
121.48 (Cporph), 126.92 (C6H5), 126.98 (Cporph), 128.10
(C6H5), 134.74, 130.95 (Cporph), 134.73 (C6H5), 137.78,
142.05, 150.33 (Cporph), 187.34 (COO), 204.45 (CO). IR
(CaF2, cm
-1): m(CO) 2,024.12 vs, 1,974.10 m, 1,940.80 vs,
m(OCO) 1,574.14 s. Anal. calcd for C94H64N10O8Ru2
(1,663.72): C, 67.86; H, 3.88; N, 8.42. Found: C, 67.54; H,
3.56; N, 8.06. Electrospray ionization mass spectrometry
(ESI-MS) (positive mode): 1,665.32 [M ? H]?.
Spectroscopic data for 2
Yield: 98 mg (59%). 1H NMR (400 MHz, CDCl3)
d = -2.75 (s, 4H, NH), 7.46–7.55 (m, 18H, HPPh3), 7.60 (d, 4H,
C6H4COO,
3J = 8 Hz), 7.77–7.84 (m, 20H, Hporph), 7.86–
7.90 (m, 12H, HPPh3), 8.01 (d, 4H, C6H4COO,
3J = 8 Hz),
8.24–8.26 (m, 12H, Hporph), 8.86–8.91 (m, 14H, Hporph).
13C {1H} NMR (100 MHz, CDCl3) d = 119.59, 120.42,
120.53, 126.88, 127.93, 128.61, 128.78, 128.82, 128.87,
130.04, 133.04, 133.65, 133.81, 133.97, 134.10, 134.16,
134.22, 134.69, 142.29, 145.50 (Cporph), 181.23 (COO),
205.78 (CO). 31P {1H} NMR (162 MHz, CDCl3)
d = 15.99 ppm. IR (CaF2, cm
-1): m(CO) 2,024.90 vs,
1,980.00 m, 1,952.73 vs, m(OCO) 1,589 s. Anal. calcd for
C130H88N8O8P2Ru25H2O (2,244.3): C, 69.57; H, 4.40; N,
4.99. Found: C, 69.24; H, 4.55; N, 4.87. ESI-MS (positive
mode): 2,154.45 [M ? H]?, 1,893.34 [M - PPh3 ? H]
?,
1,077.73 [M/2 ? H]?.
Spectroscopic data for 3
Yield: 168 mg (74%). 1H NMR (400 MHz, CDCl3):
d = -2.74 (s, 4H, NH), 4.67 (br s, 12H, CH2), 4.78 (m,
12H, CH2), 7.73–7.82 (m, 20H, Hporph), 8.23 (d, 12H,
Hporph), 8.32 (d, 4H, C6H4COO, J = 8 Hz), 8.39 (d, 4H,
C6H4COO, J = 8 Hz), 8.87 (ps, 14H, Hporph) ppm.
31P
{1H} NMR (162 MHz, CDCl3): d = -54.16 ppm.
13C
{1H} NMR (100 MHz, CDCl3): d = 52.29 (Cpta), 73.83
(Cpta), 118.99, 120.52, 120.67, 126.88, 127.93, 128.14,
131.31, 132.43, 133.29, 134.00, 134.74, 142.24, 146.20
(Cporph), 187.42 (COO), 205.24 (CO) ppm. IR (CaF2,
cm-1): m(COO) 2,023.68 vs, 1,978.33 m, 1,952.40 vs,
m(CO) 1,605.90 s, 1,588.33 m. Anal. calcd for
C106H82N8O14P2Ru2 (1,956.3): C, 65.09; H, 4.23; N, 5.73.
Found: C, 64.79; H, 4.18; N, 5.49. ESI-MS (positive
mode): 1,349.0 [M - (C45H29N4) ? H2O ? H]
?.
Spectroscopic data for 4
Yield: 105 mg (91%). 1H NMR (400 MHz, CDCl3)
d = -2.78 (s, 8H, NH), 7.63–7.79 (m, 30H, Hporph), 8.12–8.26
(m, 26H, Hporph), 8.38 (d, 4H, C6H4COO,
3J = 8 Hz), 8.61
(d, 4H, C5H4N,
3J = 6 Hz), 8.75 (d, 4H, C6H4COO,
3J = 8 Hz), 8.80–8.88 (m, 20H, Hporph), 8.89–8.96 (m,
10H, Hporph), 9.10 (m, 4H, Hporph), 9.72 (d, 4H, C5H4 N,
3J = 6 Hz). 13C {1H} NMR (100 MHz, CDCl3)
d = 96.27, 115.16, 119.35, 120.40, 120.51, 120.94, 121.41,
126.83, 127.86, 127.95, 128.55, 131.17, 134.60, 134.68,
141.88, 141.98, 142.21, 146.10, 150.55, 152.76, 180.02
(Cporph), 180.02 (COO), 204.50 (CO). IR (CaF2, cm
-1):
m(CO) 2,024.20 vs, 1,974.17 m, 1,941.78 vs, m(OCO)
1,592.64 s. Anal. calcd for C180H116N18O8Ru2CHCl3H2O
(2,980.48): C, 72.50; H, 4.00; N, 8.41. Found: C, 72.36; H,
4.38; N, 8.24. ESI-MS (positive mode): 2,862.72
[M ? H]?, 2,246.52 [M - (C43H29N5) ? H]
?, 1,466.36
[M/2 ? Cl]?.
Cell culture
Human colon (HT29), breast (MCF7, MDAMB231), lung
(A549), ovarian (Ovcar), prostate (PC3, LnCap), and
cervix (HeLa) cancer cells were obtained from the
American Tissue Type Culture Collection (Manassas, VA,
USA). A2780 ovarian cancer cells were obtained from the
ECACC (Salisbury, UK). Human Me300 melanoma and
KB head and neck cancer cells were kindly provided by D.
Rimoldi, Ludwig Institute of Cancer Research, Lausanne
branch, and by M. Barbery-Heyob, Centre Alexis Vautrin,
Nancy, France, respectively. Human uterovaginal primary
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fibroblasts were obtained from surgical biopsies of healthy
patients using the explant technique [24], according to a
protocol approved by the CHUV Ethics Committee and
patients. HT29, MCF7, MDA-MB231, A549, PC3, LnCap,
and HeLa cells were routinely grown in Dulbecco’s
modified Eagle’s medium containing 4.5 g/L glucose,
while A2780, Ovcar, Me300, and KB cells were grown in
RPMI 1640 medium. All were supplemented with 10%
heat-inactivated fetal calf serum and with antibiotics (all
from Gibco, Basel, Switzerland). The organometallic
complexes were dissolved in dimethyl sulfoxide and then
diluted in complete medium to the required concentration.
The dimethyl sulfoxide concentration did not exceed 1%
v/v and this concentration did not show any effects on
cells.
Evaluation of uptake and toxicity of the complexes
Cells in 48-well plates (Costar) were exposed at 37 C to
increasing concentrations of complexes in complete culture
medium for 48 h. After they had been washed with phos-
phate-buffered saline (PBS), the supernatants were
replaced with fresh medium and the cell-associated content
was evaluated by its porphyrin characteristic fluorescence
in a thermostated fluorescence microplate reader (Cyto-
fluor, PerSeptive BioSystems), with excitation and
emission filters set at 409 ± 5 and 645 ± 10 nm, respec-
tively, essentially as previously described [25, 26]. Cell
survival was measured using the 3-(4,5-dimethyl-2-thia-
zoyl)-2,5-diphenyltetrazolium bromide (MTT) test. MTT
(Merck) was added at 250 lg/mL and incubation was
continued for 2 h, as previously described [19]. Then the
cell culture supernatants were removed, the cell layer was
dissolved in i-PrOH/0.04 N HCl, and the absorbance at
540 nm was measured in a 96-well multiwell-plate reader
(iEMS Reader MF, Labsystems, Bioconcept, Switzerland)
and compared with the values of control cells incubated
without complexes. Experiments were conducted in tripli-
cate wells and repeated at least twice.
Fluorescence microscopy
Cells were grown on histological slides in complete med-
ium and exposed to the complexes overnight at 25 lM
concentrations. Slides were washed and incubated with the
nuclear stain 40,60-diamidino-2-phenylindolyl hydrochlo-
ride (DAPI; Roche Diagnostics, Mannheim, Germany,
1 lg/mL in PBS) for 10 min at 37 C, and examined in
PBS under a fluorescence microscope (Axioplan2, Carl
Zeiss, Feldbach, Switzerland) and filters were set at 365-
nm excitation light (BP 365/12, FT 395, LP 397) for DAPI
and 535-nm excitation light (BP 510–560, FT 580, LP 590)
for porphyrins as previously described [19, 20, 25].
Photodynamic therapy
Cells in 96-well plates (Costar) were incubated in the dark
in complete medium with 2.5 lM complexes for 24 h.
Culture medium was replaced by medium without phenol
red (Gibco) containing 5% fetal calf serum. Cells were
irradiated with a laser at 652 nm (Ceralas 652 laser diode,
Biolitec, Jena, Germany) coupled to with a frontal diffuser
(Medlight, Ecublens, Switzerland), at an irradiance of
30 mW/cm2 and with light doses ranging from 2.5 to 20 J/
cm2 as previously described [19, 20, 24, 25]. Cell survival
was assessed with the MTT assay 24 h after the end of the
irradiation and compared with values for cells irradiated
without the complexes as previously described [19]. The
LD50 (light dose necessary to induce 50% inhibition of cell
growth) values were determined after linearization using
the medium effect algorithm as described elsewhere [27].
Results
Syntheses and characterization
The thermal reaction of [Ru3(CO)12] with an excess of the
corresponding carboxylic acid HO2CR (R is CH3 and
C44H29N4) in refluxing THF yields a solution containing
the corresponding THF complexes [Ru2(CO)4(l2-g
2-
O2CR)2(THF)2]. These labile intermediates react easily
with two-electron ligands to give the stable triphenyl-
phosphine, 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane
(pta), or porphyrin-derived pyridyl analogues (Fig. 1).
Complexes 1–4 were isolated by precipitation and char-
acterized by IR, NMR, and ESI-MS as well as by elemental
analysis.
All compounds exhibit in the m(CO) region of the IR
spectrum the characteristic three-band pattern of the
Ru2(CO)4 sawhorse unit, observed in all complexes of this
type [21, 28]. Similarly, for the two carboxylato bridges
only one m(OCO) absorption is observed, in accordance with
the spectra of other [Ru2(CO)4(l2-g
2-O2CR)2L2] com-
plexes [21, 28].
Whatever the position of the porphyrin at the sawhorse
unit is, as axial ligands or as carboxylato bridges, the
chemical shift of the signal corresponding to the NH
protons in the 1H NMR spectra remains unchanged
(d = -2.75 ppm for 1 and 2, -2.74 ppm for 3, and
-2.78 ppm for 4). In the 13C {1H} NMR spectra, the peaks of
the terminal carbonyl groups and of the carboxylato bridges
are found around 180 and 205 ppm, respectively, again in
agreement with those reported in the literature [29].
The electronic spectra of porphyrin complexes 1–3
exhibit the typical four Q bands between 510 and 650 nm
and the intense Soret band around 420 nm (Table 1). The
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absorption bands of the uncoordinated porphyrin units
remain unchanged upon coordination to the dinuclear
sawhorse-type moiety, thus suggesting that there is no
perturbation of the porphyrin p-orbitals upon coordination.
The redox behavior of complexes 1, 2 and 4 was studied
by cyclic voltammetry at a platinum disc electrode. The
pertinent data are summarized in Table 2. The redox
behavior of 1 can be regarded as a superposition of the
redox response of the molecular parts: the diruthenium core
gives rise to an irreversible oxidation wave, while the
porphyrin pendants undergo an oxidation and a two con-
secutive reduction process. The assignment of the most
positive oxidation peak was not possible from the data
available. The redox changes attributable to the porphyrin
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Fig. 1 Structures of
diruthenium tetracarbonyl
porphyrin complexes 1–4
Table 1 UV–vis maximum absorption wavelength (nm) determined in dichloromethane, fluorescence quantum yields at 648 nm (/f
648) in
methanol, and singlet oxygen quantum yields (/1O2) in ethanol
Compound Soret band Q band IV Q band III Q band II Q band I /f
648 (%) /1O2 (%)
1 419 514 550 590 647 9.0 54
2 419 515 550 590 646 6.9 57
3 419 515 549 590 648 10.0 48
See Fig. 1 for the structures of 1–3
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moiety are reversible at scan rates of 0.1–1.0 V/s and occur
independently at both porphyrin pendants (i.e., as a sum of
two identical one-electron waves), which rules out any
significant electronic coupling between the porphyrin
moieties. The second reduction is probably one-electron
reduction as well but occurs at the onset of the base elec-
trolyte decomposition. It is worth noting that the B-D-E
waves (Table 2) are observed in a similar pattern and
at roughly similar potentials as for free 5-(4-pyridyl)-
10,15,20-triphenyl-21,23H-porphyrin [30]. This indicates
that coordination via the peripheral pyridine moiety has
only a minor influence (e.g., inductive) on the redox
properties of the porphyrin framework.
Complex 2 shows two oxidations possibly attributable to
the diruthenium core (A and B) followed by two reversible
oxidations localized most likely at the porphyrin units
(C and D). The subsequent oxidation (wave H) occurs
already at the onset of base electrolyted decomposition
(Fig. 2). The first oxidation (A) is observed with full
reversibility down to 0.1-V/s scan rate when scanned sep-
arately. Increasing the switching potential beyond the
second (B, irreversible) and third (C, reversible) oxidations
makes the first oxidative wave quasi-reversible (the peak
current ratio ipa/ipc increases with the scan rate) and fully
irreversible (up to 5 V/s), respectively. The redox proper-
ties of 4 correspond to the sum of those of 1 and 2.
Therefore, because of the similar redox behavior of the
individual parts, the individual redox waves overlap,
forming broad redox waves that do not allow any detailed
analysis.
Biological assays
The effect of the organometallic porphyrin complexes 1–3
was investigated in vitro in human normal fibroblastic cells
and in several human cancer cells: HeLa cervix, A2780 and
Ovcar ovarian, A549 pulmonary, Me300 melanoma, PC3
and LnCap prostate, KB head and neck, MCF7 and MDA-
MB231 breast, as well as HT29 colon cancer cells. The
poor solubility of 4 did not allow its assessment. Cells were
exposed for 48 h to increasing concentrations of com-
pounds 1–3 and their survival was determined using the
MTT cell survival assay. Representative results in human
normal fibroblastic cells and A549, HeLa, and A2780
cancer cells are shown in Fig. 3 (not shown for the other
cells). In the absence of laser exposure (dark toxicity),
compounds 1–3 did not display any cytotoxic effect in all
the cell types up to 100 lM concentration.
The uptake of compounds 1–3 was also studied by
quantification of the characteristic fluorescence of porphy-
rin derivatives (kexc/kem = 410 nm/650 nm) in cells
exposed to the complexes at concentrations from 5 to
100 lM. The results revealed that HeLa and A2780 cells
presented a good uptake profile, whereas other normal and
cancer cells presented a very low uptake of the compounds
(Fig. 3). These results were checked by fluorescence
microscopy; the fluorescence associated with porphyrin
appears red, whereas cell nuclei appear blue with DAPI
counterstaining (Fig. 4). For these compounds in all cell
lines, nuclear fragmentation was not observed, suggesting
the absence of cell apoptosis, at least for this time course.
Good accumulation of porphyrins in the cytoplasm of HeLa,
A2780, and Ovcar (not shown) cells was observed but was
not found in other cell types (only human normal fibro-
blastic cells and A549 pulmonary cell line being shown).
The phototoxic efficacy of the porphyrin complexes was
assessed at 2.5 lM concentration. Cells were incubated for
24 h with compounds 1–3 before irradiation at 652 nm
(30 mW/cm2) and light doses from 2.5 to 20 J/cm2. MTT
cell survival test was performed after a further incubation
Table 2 Summary of the electrochemical data for 1, 2 and 4 (see
Fig. 1 for the structures)
Compound E (V)
1a A ?0.56 (ir), B ?0.65 (r), C ?0.93 (r); D -1.61 (r),
E -2.02b,c
2d A ?0.22,b,e B ?0.45 (ir), C ?0.59 (r), D ?0.87 (r);
E -1.67 (r), F & -2.0
4f A ?0.25,g B ?0.47 (ir), C ?0.58 (r), D ?0.89 (r);
E -1.79 (r), F & -2.3c
The potentials are quoted relative to a ferrocene/ferrocenium refer-
ence. Peak potentials are given for irreversible (ir) processes: anodic
peak potential (Epa) for oxidations, cathodic peak potential (Epc) for
reductions. The potential for reversible (r) couples is defined as the
mean of the anodic and cathodic peak potentials: E0 = (Epa ? Epc)
a Additional wave: F Epa & ?0.23 V,
b see text, c Epc is given,
d additional waves: G -1.52 (ir), H Epa & ?1.18 V,
e E0 is given,
f additional wave: G -1.56 (ir), g Epa is given
Fig. 2 The cyclic voltammogram of 2 recorded at 0.1-V/s scan rate.
Note the difference between the first cycle (solid line) and the second
cycle (dashed line)
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Fig. 3 Porphyrin accumulation
in human cells and cytotoxicity
in the dark of 1–3. Cells were
exposed to increasing
concentrations of diruthenium
tetracarbonyl porphyrin
complexes and the increase of
characteristic porphyrin
fluorescence was recorded after
48 h of incubation (filled
squares 1, filled circles 2, filled
triangles 3). The 3-(4,5-
dimethyl-2-thiazoyl)-2,5-
diphenyltetrazolium bromide
(MTT) cell survival test was
performed at the end of the
incubation and the values
obtained were compared with
values of nonincubated cells
(open squares 1, open circles 2,
open triangles 3)
Fig. 4 Fluorescence
microscopy of human cells
exposed to diruthenium
tetracarbonyl porphyrin
complexes 1–3. Cells were
grown on histological slides and
incubated with complexes at
25 lM concentration overnight
in the dark. Compounds appear
as red fluorescence spots and
cell nuclei as blue fluorescence
after 40,60-diamidino-2-
phenylindolyl hydrochloride
counterstaining
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of 24 h. Cells treated in identical conditions but kept in the
dark, were used as controls for phototoxicity. Untreated
human cells were not photosensitive in the absence of
complexes (results not shown). The viability of cells
exposed to 1–3 and light-irradiated is shown in Fig. 5 and
the corresponding LD50 values (light dose necessary to
inhibit 50% cell survival) are presented in Table 3. The
complexes were efficient in HeLa and A2780 cells with
1.5 \ LD50 \ 6.5 J/cm
2, whereas, phototoxicities in other
cell types were very low with LD50 values of more than
15 J/cm2. In all cancer cell lines, complex 1 appeared to be
slightly more efficient. Thus, the phototoxicity results are
coherent with uptake results which showed that the com-
pounds were only taken up by HeLa and A2780 cell lines.
Thus, these types of compound present a selectivity
pattern toward female reproductive cancer cells compared
with other types of cancer cells but also compared with
human normal primary fibroblasts.
Discussion
In the present study, our aim was to develop molecules able
to combine the photosensitizing properties of porphyrins
with the organometallic effects of diruthenium carboxylate
as potential drug candidates for cancer therapy as we have
already reported for arene–ruthenium(II) moieties coordi-
nated to pyridylporphyrin derivatives [19, 20]. The
cytotoxicities of the complexes were tested in human
normal fibroblasts and in several human cancer cell lines.
Our new organometallic–porphyrin complexes displayed
no cytotoxicities in the dark for concentrations up to
100 lM for all the cell lines tested. This is in accordance
with non-porphyrin-containing diruthenium tetracarbonyl
sawhorse-type complexes which show no cytotoxicity on
the A2780 ovary carcinoma cell line [31] and with other
diruthenium carboxylate derivatives which presented some
IC50 values greater than120 lM in the HeLa cell line [32].
Interestingly, uptake studies revealed that our com-
plexes are only taken up by human HeLa cervix and A2780
ovary carcinoma cell lines and not by the other human
normal or cancer cell lines. These data were established
using the characteristic fluorescence of porphyrin deriva-
tives. Fluorescence microscopy studies also demonstrated
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Fig. 5 Photodynamic activity of compounds 1 (a), 2 (b), and 3 (c) in
human cell lines. Cells were exposed to compounds (2.5 lM) in the
dark for 24 h before being exposed to increasing doses of light at
652 nm. Then the amount of metabolically active cells was
determined 24 h later by the MTT assay. Cells not exposed to the
compounds, but irradiated, were used as controls. A549 (squares),
HeLa (triangles), A2780 (circles), and normal fibroblasts (crosses)
Table 3 LD50 values of human cells exposed to diruthenium tetra-
carbonyl porphyrin complexes 1–3
LD50 (J/cm
2)
Complexes Fibroblasts A549 HeLa A2780
1 [30 14.7 1.5 2.9
2 [30 18.6 3.6 5.4
3 [30 15.7 3.1 6.7
Cells were exposed to the complexes (2.5 lM) for 24 h in the dark,
and were then illuminated with a red laser (k = 652 nm). The 3-(4,5-
dimethyl-2-thiazoyl)-2,5-diphenyltetrazolium bromide cell survival
test was performed 24 h after the irradiation. The LD50 values (light
dose necessary to inhibit 50% cell survival) were determined using
the medium effect algorithm [27]
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that the complexes are taken up by HeLa, Ovcar, and
A2780 cells and concentrate in the cell cytoplasm and
organelles, but not in the nucleus, as did our previously
reported compounds [19, 20] but this contrasts with some
ruthenium-based drugs known to accumulate in the nucleus
[33, 34].
Photodynamic studies provided coherent results com-
pared with uptake studies since our complexes induce
phototoxicities in HeLa cervix and A2780 ovary carcinoma
cell lines and not in other cancer and normal fibroblast
cells. Moreover, our complexes appeared to be efficient
since they are active at low concentration (2.5 lM) and at
low light dose (1.5 \ LD50 \ 6.5 J/cm
2). In both cell lines,
complex 1 was found to be slightly more active than
complexes 2 and 3. The reasons for this cell specificity
remain unknown but must be attributed to the diruthenium
structure since the porphyrin alone does not have such
specificity properties. Other organometallic compounds
conjugated to hydrophobic heterocycles have already been
demonstrated to present a specificity to breast estrogen
receptors [35, 36]. Although, this is not the case for our
compounds since both MCF7 (estrogen-receptor positive)
and MDA-MB231 (estrogen-receptor negative) breast
cancer cell lines were unable to take up our compounds, we
hypothesize the targeting of another specific receptor of
female reproductive cancer cells since only cervix and
ovarian cancers are able to take up the complexes. The
reasons for this specificity are currently under investiga-
tion, but at the moment it remains unclear why the
complexes are so selective. However, these new com-
pounds are efficient photosensitizers and could provide
new hints for the design of organometallodrugs specific for
cancers of the female reproductive system that do not target
normal cells.
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